연구성과로 돌아가기
2024 연구성과별 연구자 정보 (1472 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Yoon, J. H. | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea | ABA-5127-2021 | Yoon, Jeong Hee | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Yoon, J. H. | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea | ABA-5127-2021 | Yoon, Jeong Hee | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Tak, W. Y. | Tak, WY | 13 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Suttichaimongkol, T. | Suttichaimongkol, T | 14 | Khon Kaen Univ, Dept Med, Div Gastroenterol & Hepatol, Fac Med, Khon Kaen, Thailand | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Bouattour, M. | Bouattour, M | 15 | Hop Beaujon, AP HP, Med Oncol, Paris, France | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Lin, S. M. | Lin, SM | 16 | Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Zotkiewicz, M. | Zotkiewicz, M | 17 | AstraZeneca, Late Oncol Stat, Oncol Biometr, Warsaw, Poland | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Ai, S. | Ai, S | 18 | AstraZeneca, Late Dev Oncol, Cambridge, England | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Cohen, G. J. | Cohen, GJ | 19 | AstraZeneca, Global Med Dev, Gaithersburg, MD USA | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Lencioni, R. | Lencioni, R | 20 | Univ Pisa, Dept Diagnost & Intervent Radiol, Sch Med, Pisa, Italy | ||||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Sangro, Bruno | Sangro, B | 1 | Univ Navarra Clin, Liver Unit, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Sangro, Bruno | Sangro, B | 1 | Univ Navarra Clin, HPB Oncol Area, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Sangro, Bruno | Sangro, B | 1 | CIBEREHD, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Kudo, Masatoshi | Kudo, M | 2 | Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan | AAA-9744-2019 | Kudo, Masatoshi | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Erinjeri, Joseph | Erinjeri, J | 3 | Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA | bsangro@unav.es; |
페이지 이동: